Pancreatic Cancer- Pipeline Insight, 2025

This “Pancreatic Cancer- Pipeline Insight, 2025” report provides comprehensive insights about 290+ companies and 300+ pipeline drugs in Pancreatic Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Pancreatic Cancer: Understanding

Pancreatic Cancer: Overview

Pancreatic cancer is a disease in which malignant or cancer cells form in the tissues of the pancreas. Pancreatic cancer begins in the tissues of the pancreas - an organ in the abdomen that lies behind the lower part of the stomach. Pancreatic cancer most frequently arises from pancreatic intraepithelial neoplasia (PanIN), the classic pre-neoplastic lesions, but can also arise from larger precursor lesions, namely, intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms. It exhibits aberrant autocrine and paracrine signalling cascades that promote pancreatic cancer cell proliferation, migration, invasion, and metastasis.

Pancreatic cancer also exhibits metabolic abnormalities and insensitivity to growth-inhibitory pathways. Loss of negative growth constraints is best exemplified by aberrant TGFβ signalling, which occurs due to increased expression of TGFβ isoforms. Although TGFβ is a physiological tumor suppressor, it promotes tumor progression in pancreatic cancer and many other solid tumors by exerting paracrine effects within the tumor microenvironment that lead to enhanced growth and metastasis. TGFβ can also directly induce pancreatic cancer cell proliferation by activating non-canonical signalling through mitogen-activated protein kinase (MAPK) phosphorylation, proto-oncogene tyrosine-protein kinase Src (SRC), and AKT phosphorylation, and by upregulating WNT7B expression through canonical SMAD4-dependent mechanisms.

The genes involved in the pathogenesis of pancreatic cancer can be divided into three categories: tumor-suppressor genes, oncogenes, and DNA mismatch-repair genes. Understanding these mutations is critical to better understanding familial pancreatic cancer and to developing gene-based screening tests and therapies. The most frequent genetic abnormalities in invasive pancreatic adenocarcinoma are mutational activation of Kras oncogene and inactivation of tumor suppressor genes, including CDKN2A, TP53, SMAD4, and BRCA2, widespread chromosomal losses, gene amplifications, and telomere shortening.

Chemotherapy is the main type of systemic therapy used for pancreatic cancer. However, targeted therapy and immunotherapy are occasionally used and are being studied as potential treatments in select individuals with specific molecular or genetic features. A person may receive one type of medication at a time or a combination of medications given at the same time. They can also be given as part of a treatment plan that includes surgery and/or radiation therapy. Patients with pancreatic cancer can choose from a variety of treatments. Clinical trials are being conducted to test various treatments, some of which are standard (currently used treatments). A new treatment might replace the standard one if clinical trials reveal that it is superior to the current one.

"Pancreatic Cancer- Pipeline Insight, 2025" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pancreatic Cancer pipeline landscape is provided which includes the disease overview and Pancreatic Cancer treatment guidelines. The assessment part of the report embraces, in depth Pancreatic Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pancreatic Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pancreatic Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Pancreatic Cancer.

Pancreatic Cancer Emerging Drugs Chapters

This segment of the Pancreatic Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pancreatic Cancer Emerging Drugs

Pamrevlumab: FibroGen

Pamrevlumab is a potential first-in-class antibody being developed by FibroGen that inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. The U.S. Food and Drug Administration has granted Orphan Drug Designation, and Fast Track designation to Pamrevlumab for the treatment of patients with pancreatic cancer. Currently it is in Phase III stage of clinical trial evaluation to treat Pancreatic Cancer.

• Devimistat: Cornerstone Pharmaceuticals

CPI-613 (devimistat), is designed to target the mitochondria of cancer cells in order to disrupt their energy production, cutting off the fuel for disease growth. Cancer progresses because it utilizes the mitochondria - the energy machinery of the cells - to generate the building blocks of the next tumor in order to fuel cancer growth and proliferation. Because it is designed to be highly specific, minimally toxic and effective against a wide variety of cancers, devimistat can be used for recurrent and hard-to-treat cancers, including on a chronic basis; it may also enhance the sensitivity of cancer cells to other treatment modalities, including chemotherapy. Currently, the drug is in Phase III stage of its development for the treatment of pancreatic cancer.

Masitinib: AB Science

Masitinib is a highly selective inhibitor of mast cell which gives therapeutic benefit by impacting on mast cell related remodeling of the tumor microenvironment. Masitinib is being developed in combination with chemotherapies for treatment of malignancies through its immunotherapeutic properties. The increased mast cell activity within the tumor microenvironment can promote disease progression through release of numerous pro-tumoral mediators, down-regulate the immune response to tumors, and modulation of macrophages towards a pro-tumoral state. The inhibition of the mast cell activity results in anti-tumor effect.

• SBP-101: Panbela Therapeutics

Ivospemin (SBP-101) is a proprietary polyamine analogue that, due to its unique chemical structure. It inhibits both S-adenosylmethionine decarboxylase 1 (AMD1) and ornithine decarboxylase 1 (ODC1), two key enzymes in polyamine biosynthesis, lowering intracellular polyamine concentrations and slowing or preventing targeted cell growth and division. Ivospemin provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity. The polyamine pathway at complementary junctions alter the disease. In particular, the drug have the potential to suppress and prevent tumor growth, enhance anti-tumor activity of other anti-cancer agents, and modulate the immune system. Currently, the drug is in Phase II/III stage of its development for the treatment of pancreatic cancer.

TAS-102: Taiho Pharmaceutical Co., Ltd.

TAS-102 (Lonsurf) is an oral anticancer drug, which utilizes the combination of trifluridine (FTD) and tipiracil (TPI), whose dual mechanism of action is designed to maintain clinical activity and differs from conventional fluoropyrimidines. FTD is an antineoplastic nucleoside analogue, which is incorporated directly into the DNA, thereby interfering with the function of DNA. The blood concentration of FTD is maintained via TPI, which is an inhibitor of the FTD-degrading enzyme, thymidine phosphorylase. The drug is currently in Phase II trial for the pancreatic cancer.

• RAIN-32: Rain Oncology

RAIN-32 (Milademetan), an oral small molecule, inhibitor of mouse double minute 2 (MDM2) is being developed in patients with wildtype tumor protein 53 (p53) cancers that are also exhibiting MDM2 dependence. MDM2 dependence may be occurring either through MDM2 gene amplification, protein overexpression, and loss of an MDM2 regulator or other mechanism. The company commenced an additional Phase II trial in a multicenter, single arm, open-label, and basket trial evaluating milademetan for the treatment of MDM2-amplified advanced solid tumors (MANTRA-2) including pancreatic cancer.

IMX-110: Immix Biopharma

IMX-110 is a Tissue-Specific Therapeutic™ built on ImmixBio's TME Normalization™ Technology encapsulating a poly-kinase inhibitor and apoptosis inducer delivered deep into the tumor micro-environment, or TME. ImmixBio's TME Normalization Technology enables IMX-110 to circulate in the bloodstream, then exit through porous tumor blood vessels, and accumulate in the TME. IMX-110 then simultaneously attacks all 3 components of the TME (cancer associated fibroblasts, or CAFs; tumor-associated macrophages/immune cells, or TAMs, and cancer itself), severing the critical lifelines between the tumor and its metabolic and structural support. IMX-110's TME Normalization Technology causes tumor apoptosis, a non-inflammatory tumor-cell death (vs. necroptosis, which results in repeat reignition of the inflammatory cascade leading to tumor progression).

IMX-110 is currently being evaluated in a Phase Ib/IIa open-label, dose-escalation/dose-expansion safety, tolerability and pharmacokinetic study in patients with advanced solid tumors in the United States and Australia.

Pancreatic Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Pancreatic Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pancreatic Cancer

• There are approx. 290+ key companies which are developing the therapies for Pancreatic Cancer. The companies which have their Pancreatic Cancer drug candidates in the most advanced stage, i.e. phase III include, FibroGen.

Phases

The report covers around 300+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pancreatic Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pancreatic Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pancreatic Cancer drugs.

Pancreatic Cancer Report Insights

• Pancreatic Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pancreatic Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pancreatic Cancer drugs?
• How many Pancreatic Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pancreatic Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pancreatic Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pancreatic Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• ERYtech Pharma
• Jiangsu HengRui Medicine Co., Ltd.
• FibroGen
• Novartis AG
• AB Science
• Eleison Pharmaceuticals
• Cornerstone Pharmaceuticals
• Panbela Therapeutics
• Taiho Pharmaceutical Co., Ltd.
• Rain Oncology
• Redx Pharma Plc
• Eli Lilly and Company
• Jazz Pharmaceuticals
• Immodulon Therapeutics Ltd
• GSK
• Merck Sharp & Dohme LLC
• Roche
• Helsinn Healthcare SA
• DEKA Biosciences
• Senhwa Biosciences
• Cue Biopharma
• Carisma Therapeutics Inc
• ChemoCentryx
• Boehringer Ingelheim
• Bicara Therapeutics
• Arcus Biosciences
• Mainline Biosciences
• Beijing Imunopharm Technology Co., Ltd.
• TriSalus Life Sciences
• Ono Pharmaceutical
• Exelixis
• Wellmaker Bio
• Pionyr Immunotherapeutics
• Ability Pharmaceuticals SL
• A2 Biotherapeutics
• Klus Pharma Inc.
• Nelum Corp
• Crystal Genomics Inc.
• Elicio Therapeutics
• Turning Point Therapeutics
• Immuneering Corporation
• pHion Therapeutics Ltd.
• AC BioScience
• TheraVectys
• Opna Bio
• Cytuvax
• Eureka Therapeutics

Key Products

• Eryaspase
• Fuzuloparib
• Pamrevlumab
• NIS793
• Masitinib
• Glufosfamide
• Devimistat
• SBP-101
• TAS-102
• RAIN-32
• RXC004
• LY3214996
• Lurbinectedin
• IMM-101
• GSK2256098
• Belzutifan
• Atezolizumab
• Anamorelin
• DK210
• CX-5461
• CUE-102
• CT-0508
• CCX872-B
• BI 765049
• BCA101
• AB680
• MB1707
• IM96 CAR-T cells
• SD-101
• ONO 7913
• PY159
• XL888
• WM-S1-030
• ABTL0812
• A2B530
• A166
• NLM-001
• Ivaltinostat
• ELI-002
• TPX4589
• IMM-1-104
• PTX_C1
• ACB2003.4
• Research program
• OPN-FMRP
• PanCaVax - Pancreatic Cancer Vaccine
• Research Program 2

This product will be delivered within 1-3 business days.